Rotavirus vaccines: Opportunities and challenges

@article{Grimwood2009RotavirusVO,
  title={Rotavirus vaccines: Opportunities and challenges},
  author={Keith Grimwood and Stephen B. Lambert},
  journal={Human Vaccines},
  year={2009},
  volume={5},
  pages={57 - 69}
}
Each year rotavirus gastroenteritis episodes in young children cause more than 500,000 deaths and 2.4 million hospital admissions worldwide. Vaccine development became a priority when improved personal hygiene and living standards failed to significantly reduce this disease burden. Rotavirus vaccines were developed mimicking natural immunity by protecting against severe gastroenteritis in young children, which would otherwise lead to health-care attendance, hospitalisation or even death… 
Rotavirus Infections and Vaccines
TLDR
The potential introduction ofRotavirus vaccines into the world’s poorest countries with the greatest rates of rotavirus-related mortality is expected to be very cost effective, while rotav virus vaccines should also be cost effective by international standards when incorporated into developed countries immunization schedules.
Should rotavirus vaccines be included in the national immunization program of a small developed country?
TLDR
Post-licensure monitoring of RotaTeq in theUSA and Australia report that, shortly after its introduction, there was a reduction in rotavirus disease by twothirds, greater than anticipated for the level of vaccine coverage achieved in the USA, while reduced rotav virus disease in older age groups was also observed in Australia, where initial coverage rates were much higher.
Study the Distribution of Rotavirus Genotypes in Vaccinated and non Vaccinated Children in Babylon Province
TLDR
The vaccination changes the genotype prevalence and this situation may create challenges to the effectiveness of rotavirus vaccines and planning for future polices.
Human Rotavirus Vaccine Is Highly Efficacious When Coadministered With Routine Expanded Program of Immunization Vaccines Including Oral Poliovirus Vaccine in Latin America
TLDR
RIX4414 was highly efficacious against severe rotav virus gastroenteritis caused by the circulating wild-type rotavirus (G1 and non-G1) when coadministered with routine EPI vaccines including OPV.
Rotavirus epidemiology in Queensland during the pre-vaccine era.
TLDR
Using routinely collected data, it should be possible to monitor the impact of vaccine introduction in Queensland and identify Indigenous children as having a higher burden of rotavirus illness than non-Indigenous children.
Early exposure of infants to natural rotavirus infection: a review of studies with human rotavirus vaccine RIX4414
TLDR
Serum anti-rotavirus immunoglobulin A (IgA) antibody measured in unvaccinated infants during clinical trials of RIX4414 reflects natural rotavirus exposure, and may inform the optimal timing for rotav virus vaccination.
Updates in the Prevalence of Rotavirus Gastroenteritis in Babylon City
TLDR
It is confirmed that rotavirus infection is still currently a prevalent gastroenteritis causative agent and required careful clinical attention and Pediatricians and health care providers are needed to take into account the children who at risk for developing rotav virus infection including age, residence and type of feeding.
Molecular epidemiology of rotavirus in the era of vaccination
TLDR
Minor fluctuations in rotavirus epidemiology have been observed since vaccine introduction, however, it is unclear whether these observations are due to selection pressures specific to vaccine introduction or due to natural genotype fluctuations.
Effectiveness and impact of rotavirus vaccines in Saudi Arabia: A single hospital-based study.
...
...

References

SHOWING 1-10 OF 144 REFERENCES
Rotavirus vaccines in developed countries
TLDR
Large-scale safety and efficacy studies of two new live, oral, attenuated vaccines have shown excellent efficacy against severe rotavirus gastroenteritis, and both studies detected no association with intussusception with these new vaccines when administered at the scheduled ages.
Introduction of rotavirus vaccines in developing countries: remaining challenges
TLDR
Since the majority of childhood deaths from rotavirus occur in the developing countries of Africa and Asia, widespread use of vaccine in these two continents will be necessary before a major impact on global diarrhoea mortality is seen.
Rotavirus serotypes: classification and importance in epidemiology, immunity, and vaccine development.
TLDR
The first licensed rotavirus vaccine (RRV-based quadrivalent vaccine) was designed to cover the epidemiologically important VP7 serotype 1, 2, 3, and 4, and appears to support the concept that serotype-specific antibodies to rotaviruses play an important role in protection against rotav virus-associated illnesses.
Rotavirus vaccines: targeting the developing world.
TLDR
For the global effort toward the prevention of rotavirus disease to be successful, special efforts will be required in India, China, and Indonesia, because one-third of all deaths due to rotav virus disease occur in these countries, and because these countries depend almost entirely on vaccines manufactured domestically.
Rotavirus infection in infants as protection against subsequent infections.
TLDR
In infants, natural rotavirus infection confers protection against subsequent infection, which increases with each new infection and reduces the severity of the diarrhea.
...
...